Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,983 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride (NaCl) Clear all
Completed Phase 1Phase 2 Interventional

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

NCT00616980
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
CD34-positive cells, Saline and 5% autologous plasma
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 21, 2026, 10:53 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

NCT03900325
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Nimacimab, Placebo
Drug
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Miami, Florida • Wichita, Kansas • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 10:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 10:53 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Hypertonic Saline in Posterior Spinal Fusion

NCT06822374
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis;Congenital
Interventions
Normosol-R, buffered 2% hypertonic saline
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

NCT01976585
View directory record Official record
Conditions
Low-Grade B-cell Lymphoma
Interventions
rhuFlt3L/CDX-301, Poly-ICLC
Drug
Lead sponsor
Joshua Brody
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Saline Against Lactated Ringers or Plasmalyte in the Emergency Department

NCT02614040
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy

NCT01450813
View directory record Official record
Conditions
Anesthesia, Neuromuscular Blockade
Interventions
Saline 0.06 ml/kg, Rocuronium 0.2 mg/kg, Rocuronium 0.4 mg/kg, Rocuronium 0.6 mg/kg
Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 21, 2026, 10:53 AM EDT
Terminated Phase 4 Interventional Results available

The Effect of Selenium Supplementation Among Pediatric Patients With Burns

NCT00860379
View directory record Official record
Conditions
Burns
Interventions
Selenium1, Selenium2, Placebo
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
1 Year to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 21, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

NCT04902703
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Sargramostim, Saline - placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 10:53 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Regional Anesthesia in Hip Arthroscopy

NCT02674113
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
regional anesthesia bupivacaine, regional anesthesia placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

NCT02207920
View directory record Official record
Conditions
HIV Infections
Interventions
AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
San Francisco, California • New York, New York • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 21, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional

Improving Preterm Kidney Outcomes With Caffeine

NCT07262060
View directory record Official record
Conditions
Kidney Injury, Pre-Term
Interventions
Caffeine citrate, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Hours to 96 Hours
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain

NCT02044991
View directory record Official record
Conditions
Pelvic Girdle Pain
Interventions
Corticosteroid, Placebo Injection
Drug
Lead sponsor
Loyola University
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients

NCT00671723
View directory record Official record
Conditions
Atelectasis
Interventions
Normal saline:, Hypertonic Saline, Dornase alpha
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study

NCT01996943
View directory record Official record
Conditions
Atrial Fibrillation, Alcohol
Interventions
Ethanol, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 81 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Black Widow Spider Antivenin for Patients With Systemic Latrodectism

NCT00657540
View directory record Official record
Conditions
Latrodectism
Interventions
Analatro, Saline
Drug
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
10 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
16
States / cities
Phoenix, Arizona • Davis, California • Fresno, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT05634811
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Normal Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 17 Years
Enrollment
3,547 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Ureteral Jets on Cystoscopy

NCT02476448
View directory record Official record
Conditions
Injury of Ureter
Interventions
Normal saline, Phenazopyridine, Dextrose 10%, Sodium Fluorescein
Drug
Lead sponsor
Cecilia Calvo
Other
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of SNF472 for Calciphylaxis

NCT04195906
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Experimental: SNF472, Placebo Comparator: Placebo, Experimatenl SNF472 (Open-label)
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • El Centro, California • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

NCT06297499
View directory record Official record
Conditions
Pruritus Caused by Drug
Interventions
Ondansetron 8mg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery

NCT00494832
View directory record Official record
Conditions
Spine Surgery
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT02962648
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions
Iron isomaltoside/ferric derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chula Vista, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 21, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 21, 2026, 10:53 AM EDT